由于KRAS突變的高發(fā)生率及其在啟動和維持腫瘤生長中的重要性，靶向 KRAS便成為一種理想的治療策略。

Targeting KRAS is a desirable strategy because of the high prevalence of KRAS mutations and its importance in initiating and sustaining tumor growth.

KRAS是RAS家族中最常見突變的成員， KRAS突變在多種惡性腫瘤中以不同的發(fā)生率出現(xiàn),其發(fā)病率以胰腺癌最高，其次是結(jié)直腸癌、非小細胞肺癌和膽管癌。

KRAS is the most commonly mutated member of the Ras family,KRAS mutations are seen in a variety of malignancies at different rates,its incidence is highest in pancreatic cancers,followed by coleractal cancer,NSCLC and colangiocarcinoma.

KRAS突變譜在不同癌癥類型之間存在顯著差異，98%的KRAS突變位于G12、G13或 Q61。

The profile of KRAS mutations differ significantly among diverse cancer types.98% of KRAS mutations are found at G12,G13,or Q61.

KRAS突變發(fā)生在許多具有不同突變頻率的癌癥中，但突變亞型也存在很大差異?；颊邔RAS G12抑制劑的反應(yīng)不同，暗示存在內(nèi)在耐藥性，所以需要持續(xù)探索耐藥性，以確定臨床試驗中指示適當人群和腫瘤類型的生物標志物。

KRAS mutations occur in many cancers with different mutation frequencies, but there is also a large variation in mutation subtypes. The response to KRAS G12c inhibitors in patients is different, implicating the existence of resistance. Exploration of resistance should be conducted to identify biomarkers that indicate the appropriate population and tumor type in the clinical trial.

KRAS新藥研發(fā)平臺

什么是KRAS?

美迪西助力信諾維抗腫瘤1類新藥XNW14010（小分子KRAS G12C蛋白共價結(jié)合抑制劑）獲批臨床